Clinical reference Biomarker Directory
Back to directory

C1q Complement

Established

C1q is the first classical-pathway complement component; its deficiency carries a very high lupus risk.

Also known as C1q Complement C1
In plain language

C1q is the first protein in a defense-system chain reaction called complement. People missing it almost always develop a lupus-like autoimmune disease, because without it, the body can't properly clean up its own dying cells.

Biomarker & context

C1q is the first recognition component of the classical complement pathway, binding to antibody-antigen complexes and apoptotic cell debris to initiate the complement cascade. It plays a critical role in clearing dying cells and immune complexes.

What it indicates

C1q deficiency is strongly associated with autoimmune disease: roughly 90%+ of patients with complete C1q deficiency go on to develop systemic lupus erythematosus, among the strongest known genetic risk associations for lupus, because impaired clearance of apoptotic debris and immune complexes drives autoimmunity.

Diagnosis & clinical testing

Measured via specific complement component assay, typically triggered by an abnormal CH50 (total classical pathway activity) screening test; undetectable CH50 with confirmed low C1q indicates deficiency.

Guiding treatment

Patients with confirmed C1q deficiency require close monitoring for lupus-like disease and should be counseled about this markedly elevated risk; genetic counseling is appropriate given the hereditary nature of complement deficiencies.

Clinical significance

Roughly 90%+ of C1q-deficient patients develop SLE, one of the strongest known genetic lupus risk factors.

References
  1. StatPearls. (2023). Complement Deficiency — Treatment & Management.
  2. Armando Hasudungan. (2026). Complement Deficiencies.